BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schieren G, Gambichler T, Skrygan M, Burkert B, Altmeyer P, Rump LC, Kreuter A. Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions. Am J Kidney Dis 2010;55:1040-9. [PMID: 20430497 DOI: 10.1053/j.ajkd.2010.01.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Idée J, Fretellier N, Robic C, Corot C. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Critical Reviews in Toxicology 2014;44:895-913. [DOI: 10.3109/10408444.2014.955568] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 9.4] [Reference Citation Analysis]
2 Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, Bauer WR. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:31. [PMID: 22607376 DOI: 10.1186/1532-429X-14-31] [Cited by in Crossref: 62] [Cited by in F6Publishing: 25] [Article Influence: 6.9] [Reference Citation Analysis]
3 Barnes JK, Mayes MD. Epidemiology and Environmental Risk Factors. In: Varga J, Denton CP, Wigley FM, editors. Scleroderma. Boston: Springer US; 2012. pp. 17-28. [DOI: 10.1007/978-1-4419-5774-0_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Shi X, Young CD, Zhou H, Wang X. Transforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts. Biomolecules 2020;10:E1666. [PMID: 33322749 DOI: 10.3390/biom10121666] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
5 Chopra T, Kandukurti K, Shah S, Ahmed R, Panesar M. Understanding nephrogenic systemic fibrosis. Int J Nephrol. 2012;2012:912189. [PMID: 23193473 DOI: 10.1155/2012/912189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
6 Kartamihardja AAP, Amalia SN, Sekiguchi A, Bhattarai A, Taketomi-Takahashi A, Motegi SI, Koyama H, Tsushima Y. Neutrophil elastase in the development of nephrogenic systemic fibrosis (NSF)-like skin lesion in renal failure mouse model. PLoS One 2021;16:e0259211. [PMID: 34705860 DOI: 10.1371/journal.pone.0259211] [Reference Citation Analysis]
7 Fretellier N, Idée J, Bruneval P, Guerret S, Daubiné F, Jestin G, Factor C, Poveda N, Dencausse A, Massicot F, Laprévote O, Mandet C, Bouzian N, Port M, Corot C. Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. Br J Pharmacol 2012;165:1151-62. [PMID: 21740412 DOI: 10.1111/j.1476-5381.2011.01585.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
8 Piera-Velazquez S, Wermuth PJ, Gomez-Reino JJ, Varga J, Jimenez SA. Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis. Semin Arthritis Rheum 2020;50:1226-37. [PMID: 33059296 DOI: 10.1016/j.semarthrit.2020.09.003] [Reference Citation Analysis]
9 Dendooven A, Gerritsen KG, Nguyen TQ, Kok RJ, Goldschmeding R. Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers 2011;16:289-301. [PMID: 21595567 DOI: 10.3109/1354750X.2011.561366] [Cited by in Crossref: 49] [Cited by in F6Publishing: 24] [Article Influence: 4.9] [Reference Citation Analysis]
10 Barnes JK, Mouthon L, Mayes MD. Epidemiology, Environmental, and Infectious Risk Factors. In: Varga J, Denton CP, Wigley FM, Allanore Y, Kuwana M, editors. Scleroderma. Cham: Springer International Publishing; 2017. pp. 11-24. [DOI: 10.1007/978-3-319-31407-5_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]